Source comparison
MK-677 Research Review: Dosing Protocol Comparison
Before comparing protocols, understand that the "optimal" dosing strategy depends on study objectives. IGF-1 maximization, body composition endpoints, or sleep architecture analysis each favor different approaches. Standard Evening 25mg Once daily (PM) 40–90%
This comparison does not assign a generated winner or score.
- Before comparing protocols, understand that the "optimal" dosing strategy depends on study objectives. IGF-1 maximization, body composition endpoints, or sleep architecture analysis each favor different approaches.
- Standard Evening
- 25mg
- Once daily (PM)
- 40–90%
- Moderate. Peaks at night
- Most published trials; aligns with natural GH secretion
- Best balance of efficacy and tolerability for long-duration studies (12+ weeks)
- Split Dosing
- 12.5mg × 2
- Twice daily (AM/PM)
- 35–75%
- High. Sustained ghrelin mimicry
- Sustained pulsatile GH release across 24 hours
- May reduce appetite-related dropout but increases protocol complexity
- Low-Dose Chronic
- 10–15mg
- 25–50%
- Low
- Elderly populations sensitive to side effects
- Sufficient for age-related GH decline; minimizes cortisol elevation risk
- High-Dose Short
- 30–50mg
- Once daily
- 60–110%
- Very high
- Acute metabolic challenge studies (7–14 days)
- Not sustainable long-term; side effects outweigh marginal IGF-1 gains beyond 25mg
- The split-dosing approach theoretically offers superior GH pulsatility but has never been directly compared to once-daily administration in head-to-head trials. Our assessment: stick with 25mg evening dosing unless your research specifically examines diurnal GH patterns.